Os Sensitivity Analysis Of Darolutamide, Docetaxel And Adt In Arasens

OS sensitivity analysis of darolutamide, docetaxel and ADT in ARASENS

ARASENS: dialuramide plus ADT and docetaxel for metastatic hormone-sensitive prostate cancer

ARASENS: the addition of darolutamide to ADT and docetaxel for the treatment of mHSPC

ARASENS: tolerability + pharmacokinetic analyses of combo therapy with DARO, ADT and DOC in mHSPC

Darolutamide, androgen-deprivation therapy and docetaxel demonstrate promising efficacy mHSPC

Dr Dattatreya | ARAMIS Final Analysis OS with Darolutamide Plus ADT vs Placebo Plus ADT

CRSF - Cancer Research and Statistic Foundation

ADT plus docetaxel or bisphosphonates in hormone sensitive prostate cancer: Systemic review

Darolutamide and survival in mHSPC: a plain language summary of the ARASENS study

Video Journal of Biomedicine

The role of triplet therapy in men with metastatic castration sensitive prostate cancer

ESOU Online: EAU22 highlights in prostate cancer

European Association of Urology

Effect of Darolutamide in Metastatic, Hormone-Sensitive Prostate Cancer

ARASENS: dialuramide plus ADT and docetaxel in mHSPC stratified by disease risk + volume

Final OS analysis from ARCHES

Role of the addition of docetaxel to ADT in mHSPC

Dr. Higano on Docetaxel for Hormone-Sensitive Prostate Cancer

GU ASCO Symposium 2022 Summary

Grand Rounds in Urology

Daniel M. Geynisman, MD, on the real-world analysis of abiraterone acetate & docetaxel in mHSPC

ARCHES trial overview: ADT plus enzalutamide for metastatic hormone-sensitive prostate cancer

Is There Still a Role for Docetaxel in mHSPC?

Breakthroughs for Physicians

Dr. McDermott on Rationale for Darolutamide Plus ADT/Radiation in High-Risk Prostate Cancer